Efficacy of corticosteroids in community-acquired pneumonia: A randomized double-blinded clinical trial

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 9, 2010, Pages 975-982

  Snijders, Dominic ^a   Daniels, Johannes M A ^b   De Graaff, Casper S ^a   Van Der Werf, Tjip S ^c   Boersma, Wim G ^a  

^a Location Alkmaar   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Community acquired pneumonia; Corticosteroids; Infection

Indexed keywords

ACICLOVIR; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CEFUROXIME; CIPROFLOXACIN; MOXIFLOXACIN; PLACEBO; PREDNISOLONE; ANTIINFECTIVE AGENT;

ADD ON THERAPY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SUPERINFECTION; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; COMMUNICABLE DISEASE; FEVER; HOSPITALIZATION; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA;

ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PREDNISOLONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952307234     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200905-0808OC     Document Type: Article

References (29)

1. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weisfeld LA, Kapoor WN. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-141. (Pubitemid 26021681)
2. Díaz LA, Mortensen EM, Anzueto A, Restrepo MI. Novel targets in the management of pneumonia. Ther Adv Respir Dis. 2008;2:387-400.
3. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU. Corticosteroids in the treatment of severe sepsis and septic shock in adults. JAMA 2009;301:2362-2375.
4. Sprung CL,Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
5. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995;107:1342-1349.
6. Montón C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 1999;27:1745-1753.
7. Wagner HN, Bennet IL, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 1956;98:197-215.
8. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-248.
9. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007;30:951-956.
10. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382.
11. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
12. Schouten JA, Prins JM, Bonten M, Degener JE, Janknegt R, Hollander JM, Jonkers R, Wijnands W, Verheij T, Sachs A, Kullberg BJ. (Optimizing the antibiotics policy in The Netherlands. VIII. Revised SWAB guidelines for antimicrobial therapy in adults with community-acquired pneumonia). Ned Tijdschr Geneeskd 2005;49:2495-2500.
13. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15:62-88.
14. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;13:1452-1457.
15. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, Boersma WG. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005;60:672-678.
16. Li Y, Cui X, Li X, Solomon SB, Danner RL, Banks SM, Fitz Y, Annane D, Natanson C, Eichacker PQ. Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med 2008;34:568-577.
17. Sibila O, Luna CM, Agustí C, Baquero S, Gando S, Patrón JR, Morato JG, Absi R, Bassi N, Torres A. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 2008;32:1037-1046.
18. Salluh JI, Verdeal JC, Mello GW, Araújo LV, Martins GA, de Sousa Santino M, Soares M. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med 2006;32:595-598.
19. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit CareMed 1998;158:1102-1108.
20. Gotoh S, Nishimura N, Takahashi O, Shiratsuka H, Horinouchi H, Ono H, Uchiyama N, Chohnabayashi N. Adrenal function in patients with community-acquired pneumonia. Eur Respir J 2008;31:1268-1273.
21. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, Narumoto O, Kichikawa Y, Kawai M, Tashimo H. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249-255.
22. Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC; GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008;177:1242-1247.
23. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, Newman D, Burke J, Mushtaq M, Huang A. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-2454.
24. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-1947. (Pubitemid 29288269)
25. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006;28:346-351.
26. Snijders D, van der Eerden MM, de Graaff CS, Boersma WG. The influence of COPD on mortality and severity scoring in community-acquired pneumonia. Respiration 2010;79:46-53.
27. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
28. Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2008;1:CD004418 10.1002/14651858.CD004418.pub3.
29. Feldman C, Anderson R. Therapy for pneumococcal bacteremia: monotherapy or combination therapy? Curr Opin Infect Dis 2009;22:137-142.